成瘾医学:阿片类药物使用障碍。

Q3 Medicine FP essentials Pub Date : 2024-11-01
Michelle A Carroll Turpin, Steven M Starks, Maureen O Grissom, Brian C Reed
{"title":"成瘾医学:阿片类药物使用障碍。","authors":"Michelle A Carroll Turpin, Steven M Starks, Maureen O Grissom, Brian C Reed","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Most overdose deaths in the United States involve opioids. Identification and management of opioid use disorder by primary care physicians is a critical need in health care. Substance use disorders share neurobiological dysregulation of the central motivation and reward pathway (powered by dopamine) that manifests as a cycle of addiction driven by impulse and compulsion. It is important that concern for opioid use disorder does not disrupt appropriate treatment of pain and that analgesic narcotic use is adequately monitored, especially in patients at risk of opioid use disorder. Most patients with opioid use disorder do not receive treatment. Those who do receive treatment will experience uncomfortable, but not life-threatening, symptoms of withdrawal. These symptoms can be managed with alpha2-adrenergic and opioid agonists that also reduce the reinforcement of drug use and help prolong recovery. The 2023 Mainstreaming Addiction Treatment Act removed the waiver requirement for buprenorphine prescribing, which closes the substantial gap in access to medication for opioid use disorder existing across gender, racial, and socioeconomic groups. Treatment plans that include medication for opioid use disorder have been shown to substantially reduce mortality.</p>","PeriodicalId":38325,"journal":{"name":"FP essentials","volume":"546 ","pages":"29-36"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Addiction Medicine: Opioid Use Disorder.\",\"authors\":\"Michelle A Carroll Turpin, Steven M Starks, Maureen O Grissom, Brian C Reed\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Most overdose deaths in the United States involve opioids. Identification and management of opioid use disorder by primary care physicians is a critical need in health care. Substance use disorders share neurobiological dysregulation of the central motivation and reward pathway (powered by dopamine) that manifests as a cycle of addiction driven by impulse and compulsion. It is important that concern for opioid use disorder does not disrupt appropriate treatment of pain and that analgesic narcotic use is adequately monitored, especially in patients at risk of opioid use disorder. Most patients with opioid use disorder do not receive treatment. Those who do receive treatment will experience uncomfortable, but not life-threatening, symptoms of withdrawal. These symptoms can be managed with alpha2-adrenergic and opioid agonists that also reduce the reinforcement of drug use and help prolong recovery. The 2023 Mainstreaming Addiction Treatment Act removed the waiver requirement for buprenorphine prescribing, which closes the substantial gap in access to medication for opioid use disorder existing across gender, racial, and socioeconomic groups. Treatment plans that include medication for opioid use disorder have been shown to substantially reduce mortality.</p>\",\"PeriodicalId\":38325,\"journal\":{\"name\":\"FP essentials\",\"volume\":\"546 \",\"pages\":\"29-36\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"FP essentials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"FP essentials","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

在美国,大多数因用药过量而导致的死亡都与阿片类药物有关。初级保健医生对阿片类药物使用障碍的识别和管理是医疗保健领域的一项重要需求。物质使用障碍与中枢动机和奖赏通路(由多巴胺驱动)的神经生物学失调有共同之处,表现为由冲动和强迫驱动的成瘾循环。重要的是,对阿片类药物使用障碍的关注不能影响对疼痛的适当治疗,并且要对镇痛麻醉剂的使用进行充分监控,尤其是有阿片类药物使用障碍风险的患者。大多数患有阿片类药物使用障碍的患者都没有接受治疗。接受治疗的患者会出现不适的戒断症状,但不会危及生命。这些症状可以通过使用α2-肾上腺素能和阿片类激动剂来控制,这些药物还能减少吸毒的强化作用,有助于延长康复时间。2023 年成瘾治疗主流化法案》取消了丁丙诺啡处方的豁免要求,从而缩小了不同性别、种族和社会经济群体在获得阿片类药物使用障碍药物治疗方面存在的巨大差距。事实证明,包含阿片类药物使用障碍药物治疗的治疗计划可大幅降低死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Addiction Medicine: Opioid Use Disorder.

Most overdose deaths in the United States involve opioids. Identification and management of opioid use disorder by primary care physicians is a critical need in health care. Substance use disorders share neurobiological dysregulation of the central motivation and reward pathway (powered by dopamine) that manifests as a cycle of addiction driven by impulse and compulsion. It is important that concern for opioid use disorder does not disrupt appropriate treatment of pain and that analgesic narcotic use is adequately monitored, especially in patients at risk of opioid use disorder. Most patients with opioid use disorder do not receive treatment. Those who do receive treatment will experience uncomfortable, but not life-threatening, symptoms of withdrawal. These symptoms can be managed with alpha2-adrenergic and opioid agonists that also reduce the reinforcement of drug use and help prolong recovery. The 2023 Mainstreaming Addiction Treatment Act removed the waiver requirement for buprenorphine prescribing, which closes the substantial gap in access to medication for opioid use disorder existing across gender, racial, and socioeconomic groups. Treatment plans that include medication for opioid use disorder have been shown to substantially reduce mortality.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
FP essentials
FP essentials Medicine-Medicine (all)
CiteScore
1.00
自引率
0.00%
发文量
58
期刊最新文献
Female Pelvic Conditions: Dyspareunia and Vulvodynia. Female Pelvic Conditions: Foreword. Female Pelvic Conditions: Interstitial Cystitis/Bladder Pain Syndrome. Female Pelvic Conditions: Sexually Transmitted Infections. Female Pelvic Conditions: Urinary Incontinence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1